← Centessa Pharmaceuticals plc
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Net Income From Continuing Operations | ($10.7m) | ($381.1m) | ($216.2m) | ($151.1m) | ($235.8m) | ($197.5m) | ($250.6m) | |
| Net loss | ($10.7m) | ($381.1m) | ($216.2m) | ($151.1m) | ($235.8m) | ($197.5m) | — | |
| Depreciation, Depletion and Amortization | $0 | $34k | $131k | $810k | $942k | $921k | $943k | |
| Depreciation | $0 | $34k | $131k | $298k | $300k | $300k | $943k | |
| Amortization of Debt Issuance Costs and Discounts | — | — | — | — | — | $1.2m | — | |
| Capitalized Computer Software, Amortization | — | — | — | $500k | $600k | $600k | — | |
| Amortization of discount of marketable securities | — | — | — | — | $0 | ($1.8m) | — | |
| Amortization of debt issuance costs and exit fee of long-term debt | — | — | — | — | $0 | $1.2m | — | |
| Amortization Of Securities | — | — | — | — | $0 | ($1.8m) | $1.1m | |
| Depreciation Amortization Depletion | — | — | $131k | $810k | $942k | $921k | $943k | |
| Deferred Income Tax Expense (Benefit) | — | — | ($2.9m) | ($26.5m) | $2.7m | $2.5m | $2.3m | |
| Change in deferred taxes | — | — | ($2.9m) | ($26.5m) | $2.7m | $2.5m | — | |
| Share-based Payment Arrangement, Noncash Expense | $336k | $14.9m | $25.0m | $29.4m | $33.5m | $31.0m | $33.6m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | $4.8m | — | |
| Share-based Payment Arrangement, Expense | $336k | $14.9m | $25.0m | $29.4m | $33.5m | $31.0m | $33.6m | |
| Share-based compensation expense | $336k | $14.9m | $25.0m | $29.4m | $33.5m | $31.0m | $33.6m | |
| Other Nonoperating Income (Expense) | $155k | ($4.4m) | $2.3m | ($5.4m) | ($1.7m) | $2.9m | — | |
| Changes in operating assets and liabilities: | ||||||||
| Change In Working Capital | — | — | ($2.8m) | ($18.9m) | $22.1m | ($30.0m) | $2.7m | |
| Change In Receivables | — | — | ($11.7m) | ($12.1m) | ($6.6m) | ($7.3m) | ($6.6m) | |
| Increase (Decrease) in Accounts Payable | ($49k) | $4.2m | $6.4m | ($2.7m) | ($4.6m) | $50k | $5.4m | |
| Change In Payables And Accrued Expense | — | — | $12.6m | ($3.5m) | $18.2m | ($15.2m) | $5.4m | |
| Accrued expenses and other liabilities | $653k | $13.0m | $6.3m | ($797k) | $22.8m | ($15.2m) | — | |
| Change In Accrued Expense | — | — | $6.3m | ($797k) | $22.8m | ($15.2m) | $5.3m | |
| Prepaid expenses and other assets | $306k | ($16.2m) | ($3.7m) | ($1.4m) | $10.2m | ($7.9m) | — | |
| Change In Other Current Assets | — | — | $0 | ($1.9m) | $298k | $253k | $241k | |
| Net Cash Provided by (Used in) Operating Activities | ($10.6m) |
($135.1m)
-1171.02%
|
($200.5m)
-48.43%
|
($160.3m)
+20.05%
|
($142.1m)
+11.40%
|
($193.8m)
-36.44%
|
($208.8m)
-7.73%
|
|
| Cash flows from investing activities: | ||||||||
| Payments to Acquire Property, Plant, and Equipment | $0 | $186k | $1.1m | $169k | $34k | $371k | ($371k) | |
| Purchases of investments in marketable securities | — | — | $0 | ($264.9m) | ($140.5m) | ($739.8m) | — | |
| Proceeds from maturities of investments in marketable securities | — | — | $0 | $138.1m | $171.8m | $321.6m | — | |
| Payments for (Proceeds from) Other Investing Activities | — | — | ($206k) | $0 | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | $0 | $63.3m | ($931k) | ($127.0m) | $31.3m | ($418.5m) | ($153.4m) | |
| Cash flows from financing activities: | ||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | ($34.1m) | $0 | — | |
| Loss on extinguishment of debt | — | — | — | $0 | $34.1m | $0 | — | |
| Proceeds from issuance of debt, net of issuance costs | $1.4m | $73.9m | $0 | $0 | $109.3m | $0 | $0 | |
| Long Term Debt Issuance | — | — | $0 | $0 | $109.3m | $0 | $0 | |
| Net Issuance Payments Of Debt | — | — | $0 | $0 | ($762k) | $0 | $0 | |
| Repayment of debt | — | — | — | $0 | ($110.1m) | $0 | $0 | |
| Long Term Debt Payments | — | — | — | $0 | ($110.1m) | $0 | $0 | |
| Issuance Of Capital Stock | — | — | $0 | $20.8m | $359.6m | $275.4m | $269.2m | |
| Proceeds from Issuance of Common Stock | — | — | — | $20.8m | — | — | $269.2m | |
| Common Stock Issuance | — | — | $0 | $20.8m | $359.6m | $275.4m | $269.2m | |
| Payments for Repurchase of Common Stock | $0 | $12k | — | — | — | — | — | |
| Proceeds from (Payments for) Other Financing Activities | — | — | ($261k) | $0 | ($5.3m) | ($401k) | — | |
| Net Other Financing Charges | — | — | ($261k) | — | ($5.3m) | ($5.2m) | ($4.1m) | |
| Net Cash Provided by (Used in) Financing Activities | $1.4m |
$660.1m
+48368.94%
|
$457k
-99.93%
|
$21.1m
+4520.79%
|
$364.8m
+1627.29%
|
$291.5m
-20.08%
|
$318.9m
+9.39%
|
|
| Net (decrease) increase in cash, cash equivalents, and restricted cash | ($9.3m) | $590.1m | ($201.4m) | ($265.6m) | $255.2m | ($321.3m) | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($9.3m) | $590.1m | ($201.4m) | ($265.6m) | $255.2m | ($321.3m) | $61.8m | |
| Beginning Cash Position | — | — | $595.1m | $393.6m | $128.0m | $383.2m | $105.2m | |
| Cash, cash equivalents, and restricted cash at beginning of period | $7.2m | $595.1m | $393.6m | $128.0m | $383.2m | $62.0m | — | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($75k) | $1.8m | ($418k) | $615k | $1.2m | ($448k) | $1.3m | |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | ($75k) | $1.8m | ($418k) | $615k | $1.2m | ($448k) | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $7.2m | $595.1m | $393.6m | $128.0m | $383.2m | $62.0m | $61.8m | |
| Effect Of Exchange Rate Changes | — | — | ($418k) | $615k | $1.2m | ($448k) | $1.3m | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Income Tax Expense (Benefit) | $0 | $114k | ($747k) | ($25.1m) | $2.8m | $1.8m | — | |
| Interest Expense Nonoperating | — | — | — | — | $10.1m | $11.5m | — | |
| Operating Lease, Expense | — | — | — | $1.6m | — | — | — | |
| Operating leases, net | — | — | $0 | ($1.9m) | $298k | $253k | — | |
| Operating lease payments reducing operating lease liabilities | — | — | $0 | $1.2m | $1.6m | $1.6m | — | |
| Additional Financial Items | ||||||||
| Proceeds from Stock Options Exercised | $0 | $779k | $718k | $310k | $11.2m | $21.4m | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | ($3.6m) | ($2.8m) | $800k | ($1.8m) | $2.9m | — | |
| General and Administrative Expense | $1.1m | $42.9m | $55.2m | $53.7m | $50.8m | $50.5m | — | |
| Investment Income, Interest | — | — | — | — | $14.0m | $20.5m | — | |
| Change in fair value of financial instruments | $186k | $15.8m | ($3.9m) | $5.9m | $300k | $0 | — | |
| Tax incentive receivable | ($1.5m) | ($6.8m) | ($11.7m) | ($12.1m) | ($6.6m) | ($7.3m) | — | |
| Other, net | $1k | $0 | ($261k) | $0 | ($5.3m) | ($401k) | — | |
| Proceeds from issuance of shares, net of issuance costs | — | — | $0 | $20.8m | $359.6m | $275.4m | — | |
| Payment of employee withholding taxes related to withheld shares for stock based compensation plans | — | — | — | — | ($5.3m) | ($4.8m) | — | |
| Proceeds from option exercises | $0 | $779k | $718k | $310k | $11.2m | $21.4m | — | |
| Cash Flow From Continuing Financing Activities | — | — | $457k | $21.1m | $364.8m | $291.5m | $318.9m | |
| Cash Flow From Continuing Investing Activities | — | — | ($931k) | ($127.0m) | $31.3m | ($418.5m) | ($153.4m) | |
| Change In Account Payable | — | — | $6.4m | ($2.7m) | ($4.6m) | $50k | $5.4m | |
| Change In Payable | — | — | $6.4m | ($2.7m) | ($4.6m) | $50k | $5.4m | |
| Change In Prepaid Assets | — | — | ($3.7m) | ($1.4m) | $10.2m | ($7.9m) | ($1.6m) | |
| Changes In Cash | — | — | ($201.0m) | ($266.2m) | $254.0m | ($320.8m) | ($43.3m) | |
| End Cash Position | — | — | $393.6m | $128.0m | $383.2m | $62.0m | $61.8m | |
| Financing Cash Flow | — | — | $457k |
$21.1m
+4520.79%
|
$364.8m
+1627.29%
|
$291.5m
-20.08%
|
$318.9m
+9.39%
|
|
| Free Cash Flow | — | — | ($201.7m) | ($160.5m) | ($142.1m) | ($194.2m) | ($209.2m) | |
| Investing Cash Flow | — | — | ($931k) | ($127.0m) | $31.3m | ($418.5m) | ($153.4m) | |
| Net PPE Purchase And Sale | — | — | ($1.1m) | ($169k) | ($34k) | ($371k) | ($160k) | |
| Other Non Cash Items | — | — | $173k | $28k | $62k | $1.1m | — | |
| Proceeds From Stock Option Exercised | — | — | $718k | $310k | $11.2m | $21.4m | $53.7m | |
| Purchase Of PPE | — | — | ($1.1m) | ($169k) | ($34k) | ($371k) | ($371k) | |
| Stock Based Compensation | — | — | $25.0m | $29.4m | $33.5m | $31.0m | $33.6m | |
| Unrealized Gain Loss On Investment Securities | — | — | ($3.9m) | $5.9m | $300k | $0 | ($500k) | |
| Net Investment Purchase And Sale | — | — | $0 | ($126.8m) | $31.3m | ($418.2m) | ($153.1m) | |
| Purchase Of Investment | — | — | $0 | ($264.9m) | ($140.5m) | ($739.8m) | ($517.8m) | |
| Sale Of Investment | — | — | $0 | $138.1m | $171.8m | $321.6m | $364.8m | |
| Supplemental disclosure of cash flow information: | ||||||||
| Change In Cash Supplemental As Reported | — | — | ($201.4m) | ($265.6m) | $255.2m | ($321.3m) | — | |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $0 | $1.5m | $7.3m | $9.9m | $10.1m | $9.5m | — | |
| Income taxes paid | — | $0 | $1.3m | $2.9m | $82k | $1.3m | — |